Misplaced Pages

Cyanocobalamin

Skeletal formula
Stick model of cyanocobalamin based on the crystal structure
Clinical data
Pronunciation	sye AN oh koe BAL a min
Trade names	Cobolin-M, Depo-Cobolin, others
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a604029
License data	US DailyMed: Cyanocobalamin
Pregnancy category	AU: Exempt
Routes of administration	By mouth, intramuscular, nasal spray
ATC code	B03BA01 (WHO)
Legal status
Legal status	US: OTC / Rx-only
Identifiers
CAS Number	68-19-9
PubChem CID	16212801
DrugBank	DB00115
ChemSpider	24921423
UNII	P6YC3EG204
KEGG	D00166
ChEMBL	ChEMBL2110563
ECHA InfoCard	100.000.618
Chemical and physical data
Formula	C63H88CoN14O14P
Molar mass	1355.388 g·mol
3D model (JSmol)	Interactive image
Melting point	300 °C (572 °F) +
Boiling point	300 °C (572 °F) +
Solubility in water	1/80g/ml
SMILES CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)()OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.#N.
InChI InChI=1S/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;-1;+3/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57?,59-,60+,61+,62+;;/m1../s1 Key:FDJOLVPMNUYSCM-QJRSUKKJSA-L

Cyanocobalamin is a form of vitamin B
₁₂ used to treat and prevent vitamin B
₁₂ deficiency except in the presence of cyanide toxicity. The deficiency may occur in pernicious anemia, following surgical removal of the stomach, with fish tapeworm, or due to bowel cancer. It is used by mouth, by injection into a muscle, or as a nasal spray.

Cyanocobalamin is generally well tolerated. Minor side effects may include diarrhea, nausea, upset stomach, and itchiness. Serious side effects may include anaphylaxis, and low blood potassium resulting in heart failure. Use is not recommended in those who are allergic to cobalt or have Leber's disease. No overdosage or toxicity has been reported. It is less preferred than hydroxocobalamin for treating vitamin B
₁₂ deficiency because it has a slightly lower bioavailability. Some studies have shown it to possess an antihypotensive effect. Vitamin B
₁₂ is an essential nutrient meaning that it cannot be made by the body but is required for life.

Cyanocobalamin was first manufactured in the 1940s. It is available as a generic medication and over the counter. In 2022, it was the 131st most commonly prescribed medication in the United States, with more than 4 million prescriptions.

Medical use

Cyanocobalamin is usually prescribed after surgical removal of part or all of the stomach or intestine to ensure adequate serum levels of vitamin B
₁₂. It is also used to treat pernicious anemia, vitamin B
₁₂ deficiency (due to low intake from food or inability to absorb due to genetic or other factors), thyrotoxicosis, hemorrhage, malignancy, liver disease and kidney disease. Cyanocobalamin injections are often prescribed to gastric bypass patients who have had part of their small intestine bypassed, making it difficult for B
₁₂ to be acquired via food or vitamins. Cyanocobalamin is also used to perform the Schilling test to check ability to absorb vitamin B
₁₂.

Cyanocobalamin is also produced in the body (and then excreted via urine) after intravenous hydroxycobalamin is used to treat cyanide poisoning.

Side effects

Possible side effects of cyanocobalamin injection include allergic reactions such as hives, difficult breathing; redness of the face; swelling of the arms, hands, feet, ankles or lower legs; extreme thirst; and diarrhea. Less-serious side effects may include headache, dizziness, leg pain, itching, or rash.

Treatment of megaloblastic anemia with concurrent vitamin B
₁₂ deficiency using B
₁₂ vitamers (including cyanocobalamin), creates the possibility of hypokalemia due to increased erythropoiesis (red blood cell production) and consequent cellular uptake of potassium upon anemia resolution. When treated with cyanocobalamin, patients with Leber's disease may develop serious optic atrophy, possibly leading to blindness.

Chemistry

Vitamin B
₁₂ is the "generic descriptor" name for any vitamers of vitamin B
₁₂. Animals, including humans, can convert cyanocobalamin to any one of the active vitamin B
₁₂ compounds.

Cyanocobalamin is one of the most widely manufactured vitamers in the vitamin B
₁₂ family (the family of chemicals that function as B
₁₂ when put into the body), because cyanocobalamin is the most air-stable of the B
₁₂ forms. It is the easiest to crystallize and therefore easiest to purify after it is produced by bacterial fermentation. It can be obtained as dark red crystals or as an amorphous red powder. Cyanocobalamin is hygroscopic in the anhydrous form, and sparingly soluble in water (1:80). It is stable to autoclaving for short periods at 121 °C (250 °F). The vitamin B
₁₂ coenzymes are unstable in light. After consumption the cyanide ligand is replaced by other groups (adenosyl, methyl) to produce the biologically active forms. The cyanide is converted to thiocyanate and excreted by the kidney.

Chemical reactions

In the cobalamins, cobalt normally exists in the trivalent state, Co(III). However, under reducing conditions, the cobalt center is reduced to Co(II) or even Co(I), which are usually denoted as B
_12r and B
_12s, for reduced and super reduced respectively.

B
_12r and B
_12s can be prepared from cyanocobalamin by controlled potential reduction, or chemical reduction using sodium borohydride in alkaline solution, zinc in acetic acid, or by the action of thiols. Both B
_12r and B
_12s are stable indefinitely under oxygen-free conditions. B
_12r appears orange-brown in solution, while B
_12s appears bluish-green under natural daylight, and purple under artificial light.

B
_12s is one of the most nucleophilic species known in aqueous solution. This property allows the convenient preparation of cobalamin analogs with different substituents, via nucleophilic attack on alkyl halides and vinyl halides.

For example, cyanocobalamin can be converted to its analog cobalamins via reduction to B
_12s, followed by the addition of the corresponding alkyl halides, acyl halides, alkene or alkyne. Steric hindrance is the major limiting factor in the synthesis of the B
₁₂ coenzyme analogs. For example, no reaction occurs between neopentyl chloride and B
_12s, whereas the secondary alkyl halide analogs are too unstable to be isolated. This effect may be due to the strong coordination between benzimidazole and the central cobalt atom, pulling it down into the plane of the corrin ring. The trans effect determines the polarizability of the Co–C bond so formed. However, once the benzimidazole is detached from cobalt by quaternization with methyl iodide, it is replaced by H
₂O or hydroxyl ions. Various secondary alkyl halides are then readily attacked by the modified B
_12s to give the corresponding stable cobalamin analogs. The products are usually extracted and purified by phenol-methylene chloride extraction or by column chromatography.

Cobalamin analogs prepared by this method include the naturally occurring coenzymes methylcobalamin and cobamamide, and other cobalamins that do not occur naturally, such as vinylcobalamin, carboxymethylcobalamin and cyclohexylcobalamin. This reaction is under review for use as a catalyst for chemical dehalogenation, organic reagent and photosensitized catalyst systems.

Production

Cyanocobalamin is commercially prepared by bacterial fermentation. Fermentation by a variety of microorganisms yields a mixture of methylcobalamin, hydroxocobalamin and adenosylcobalamin. These compounds are converted to cyanocobalamin by addition of potassium cyanide in the presence of sodium nitrite and heat. Since multiple species of Propionibacterium produce no exotoxins or endotoxins and have been granted GRAS status (generally regarded as safe) by the United States Food and Drug Administration, they are the preferred bacterial fermentation organisms for vitamin B
₁₂ production.

Historically, the physiological form was initially thought to be cyanocobalamin. This was because hydroxocobalamin produced by bacteria was changed to cyanocobalamin during purification in activated charcoal columns after separation from the bacterial cultures (because cyanide is naturally present in activated charcoal). Cyanocobalamin is the form in most pharmaceutical preparations because adding cyanide stabilizes the molecule.

The total world production of vitamin B₁₂, by four companies (the French Sanofi-Aventis and three Chinese companies) in 2008 was 35 tonnes.

Metabolism

The two bioactive forms of vitamin B
₁₂ are methylcobalamin in cytosol and adenosylcobalamin in mitochondria. Multivitamins often contain cyanocobalamin, which is presumably converted to bioactive forms in the body. Both methylcobalamin and adenosylcobalamin are commercially available as supplement pills. The MMACHC gene product catalyzes the decyanation of cyanocobalamin as well as the dealkylation of alkylcobalamins including methylcobalamin and adenosylcobalamin. This function has also been attributed to cobalamin reductases. The MMACHC gene product and cobalamin reductases enable the interconversion of cyano- and alkylcobalamins.

Cyanocobalamin is added as an ingredient to fortify nutrition in products such as baby formula, breakfast cereals and energy drinks as well as livestock feed. Vitamin B
₁₂ becomes inactive when exposed to hydrogen cyanide and nitric oxide in cigarette smoke. Vitamin B
₁₂ deficiency can develop with heavy regular use of nitrous oxide N
₂O, also known as "laughing gas", used for anaesthesia in a clinical setting or as a propellant gas, it's commonly abused as a recreational drug. Vitamin B
₁₂ additionally becomes inactive when exposed to intense heat or electromagnetic radiation.

In the cytosol

Methylcobalamin and 5-methyltetrahydrofolate are needed by methionine synthase in the methionine cycle to transfer a methyl group from 5-methyltetrahydrofolate to homocysteine, thereby generating tetrahydrofolate (THF) and methionine, which is used to make SAMe. SAMe is the universal methyl donor and is used for DNA methylation and to make phospholipid membranes, choline, sphingomyelin, acetylcholine, and other neurotransmitters.

In mitochondria

The enzymes that use B
₁₂ as a built-in cofactor are methylmalonyl-CoA mutase (PDB 4REQ) and methionine synthase (PDB 1Q8J).

The metabolism of propionyl-CoA occurs in the mitochondria and requires Vitamin B
₁₂ (as adenosylcobalamin) to make succinyl-CoA. When the conversion of propionyl-CoA to succinyl-CoA in the mitochondria fails due to Vitamin B
₁₂ deficiency, elevated blood levels of methylmalonic acid (MMA) occur. Thus, elevated blood levels of homocysteine and MMA may both be indicators of vitamin B
₁₂ deficiency.

Adenosylcobalamin is needed as cofactor in methylmalonyl-CoA mutase—MUT enzyme. Processing of cholesterol and protein gives propionyl-CoA that is converted to methylmalonyl-CoA, which is used by MUT enzyme to make succinyl-CoA. Vitamin B
₁₂ is needed to prevent anemia, since making porphyrin and heme in mitochondria for producing hemoglobin in red blood cells depends on succinyl-CoA made by vitamin B
₁₂.

Absorption and transport

Inadequate absorption of vitamin B
₁₂ may be related to coeliac disease. Intestinal absorption of vitamin B
₁₂ requires successively three different protein molecules: haptocorrin, intrinsic factor and transcobalamin II.

See also

• Methylcobalamin
• Hydroxocobalamin
• Adenosylcobalamin
• Cobalamin biosynthesis

References

1. Prieto L, Neuburger M, Spingler B, Zelder F (October 2016). "Inorganic Cyanide as Protecting Group in the Stereospecific Reconstitution of Vitamin B₁₂ from an Artificial Green Secocorrinoid" (PDF). Organic Letters. 18 (20): 5292–5295. doi:10.1021/acs.orglett.6b02611. PMID 27726382.
2. ^ "Vitamin B12 Injection: Side Effects, Uses & Dosage". Drugs.com. Retrieved 19 April 2019.
3. "Cyanocobalamin – Drug Usage Statistics, United States, 2006–2016". ClinCalc.com. Retrieved 9 November 2019.
4. "Therapeutic goods exempted from pregnancy categorisation". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 20 May 2024.
5. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 993–994. ISBN 9780857113382.
6. ^ "Cyanocobalamin Side Effects in Detail". Drugs.com. Retrieved 19 April 2019.
7. Linnell JC, Matthews DM, England JM (November 1978). "Therapeutic misuse of cyanocobalamin". Lancet. 2 (8098): 1053–1054. doi:10.1016/s0140-6736(78)92379-6. PMID 82069. S2CID 29703726.
8. Herbert V (September 1988). "Vitamin B-12: plant sources, requirements, and assay". The American Journal of Clinical Nutrition. 48 (3 Suppl): 852–858. doi:10.1093/ajcn/48.3.852. PMID 3046314.
9. ^ "DailyMed – cyanocobalamin, isopropyl alcohol". dailymed.nlm.nih.gov. Retrieved 19 April 2019.
10. ^ Lilley LL, Collins SR, Snyder JS (2019). Pharmacology and the Nursing Process E-Book. Elsevier Health Sciences. p. 83. ISBN 9780323550468.
11. ^ "Cyanocobalamin - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 19 April 2019.
12. Markle HV (1996). "Cobalamin". Critical Reviews in Clinical Laboratory Sciences. 33 (4): 247–356. doi:10.3109/10408369609081009. PMID 8875026.
13. Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux S (2014). Nathan and Oski's Hematology and Oncology of Infancy and Childhood E-Book. Elsevier Health Sciences. p. 309. ISBN 9780323291774.
14. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
15. "Cyanocobalamin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
16. Cyanocobalamin. University of Maryland Medical Center
17. MacLennan L, Moiemen N (February 2015). "Management of cyanide toxicity in patients with burns". Burns. 41 (1): 18–24. doi:10.1016/j.burns.2014.06.001. PMID 24994676.
18. "Cyanocobalamin Injection". MedlinePlus. Archived from the original on 19 April 2015. Retrieved 4 July 2015.
19. "Clinical Vitamin B12 Deficiency. Managing Patients". Centers for Disease Control and Prevention. Archived from the original on 26 April 2015. Retrieved 4 July 2015.
20. "Vitamin B12". MedlinePlus. Archived from the original on 5 April 2015. Retrieved 4 July 2015.
21. Quadros EV (January 2010). "Advances in the understanding of cobalamin assimilation and metabolism". British Journal of Haematology. 148 (2): 195–204. doi:10.1111/j.1365-2141.2009.07937.x. PMC 2809139. PMID 19832808.
22. "Cyanocobalamin Injection". Empower Pharmacy. Retrieved 2 April 2021.
23. "Vitamin B12 (Cyanocobalamin)". +Medicine LibreTexts. 12 May 2017. Retrieved 2 April 2021.
24. "TERMIUM Plus®". Canada.ca. Government of Canada. 8 October 2009. Retrieved 2 April 2021.
25. "Nascobal® (Cyanocobalamin, USP) Nasal Spray 500 mcg/spray 0.125 mL Rx only" (PDF). Access Data FDA. Retrieved 2 April 2021.
26. Pimenta E, Calhoun DA, Oparil S (2010). "Chapter 28: Hypertensive emergencies". In Jeremias A, Brown DL (eds.). Cardiac Intensive Care (2nd ed.). Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4160-3773-6.
27. ^ Dolphin D (January 1971). "[205] Preparation of the reduced forms of vitamin B12 and of some analogs of the vitamin B12 coenzyme containing a cobalt-carbon bond". In McCormick DB, Wright LD (eds.). Preparation of the reduced forms of vitamin B12 and of some analogs of the vitamin B12 coenzyme containing a cobalt-carbon bond. Methods in Enzymology. Vol. 18. Academic Press. pp. 34–52. doi:10.1016/S0076-6879(71)18006-8. ISBN 9780121818821.
28. Brodie JD (February 1969). "On the mechanism of catalysis by vitamin B12". Proceedings of the National Academy of Sciences of the United States of America. 62 (2): 461–467. Bibcode:1969PNAS...62..461B. doi:10.1073/pnas.62.2.461. PMC 277821. PMID 5256224.
29. Shimakoshi H, Hisaeda Y. "Environmental-friendly catalysts learned from Vitamin B
    ₁₂-dependent enzymes" (PDF). Tcimail. 128: 2.
30. Riaz M, Ansari ZA, Iqbal F, Akram M (2007). "Microbial production of vitamin B12 by methanol utilizing strain of Pseudomonas specie". Pak J. Biochem. Mol. Biol. 40: 5–10. Archived from the original on 25 April 2012. Retrieved 31 October 2017.
31. Linnell JC, Matthews DM (February 1984). "Cobalamin metabolism and its clinical aspects". Clinical Science. 66 (2): 113–121. doi:10.1042/cs0660113. PMID 6420106.
32. Herbert V (September 1988). "Vitamin B-12: plant sources, requirements, and assay". The American Journal of Clinical Nutrition. 48 (3 Suppl): 852–858. doi:10.1093/ajcn/48.3.852. PMID 3046314.
33. Zhang Y (26 January 2009). "New round of price slashing in vitamin B₁₂ sector (Fine and Specialty)". China Chemical Reporter. Archived from the original on 13 May 2013.
34. Hannibal L, Kim J, Brasch NE, Wang S, Rosenblatt DS, Banerjee R, et al. (August 2009). "Processing of alkylcobalamins in mammalian cells: A role for the MMACHC (cblC) gene product". Molecular Genetics and Metabolism. 97 (4): 260–266. doi:10.1016/j.ymgme.2009.04.005. PMC 2709701. PMID 19447654.
35. Watanabe F, Nakano Y (1997). "Purification and characterization of aquacobalamin reductases from mammals". Vitamins and Coenzymes Part K. Methods in Enzymology. Vol. 281. pp. 295–305. doi:10.1016/S0076-6879(97)81036-1. ISBN 9780121821821. PMID 9250994.
36. Quadros EV, Jackson B, Hoffbrand AV, Linnell JC (8 October 2019). "Interconversion of cobalamins in human lymphocytes in vitro and the influence of nitrous oxide on synthesis of cobalamin coenzymes". In Zagalak B, Friedrich W (eds.). Vitamin B12, Proceedings of the Third European Symposium on Vitamin B12 and Intrinsic Factor. De Gruyter. pp. 1045–1054. doi:10.1515/9783111510828-118. ISBN 978-3-11-151082-8.
37. "DSM in Food, Beverages & Dietary Supplements". DSM. Retrieved 2 March 2015.
38. Thompson AG, Leite MI, Lunn MP, Bennett DL (June 2015). "Whippits, nitrous oxide and the dangers of legal highs". Practical Neurology. 15 (3): 207–209. doi:10.1136/practneurol-2014-001071. PMC 4453489. PMID 25977272.
39. Watanabe F, Abe K, Fujita T, Goto M, Hiemori M, Nakano Y (January 1998). "Effects of Microwave Heating on the Loss of Vitamin B(12) in Foods". Journal of Agricultural and Food Chemistry. 46 (1): 206–210. Bibcode:1998JAFC...46..206W. doi:10.1021/jf970670x. PMID 10554220. S2CID 23096987.
40. Mancia F, Evans PR (June 1998). "Conformational changes on substrate binding to methylmalonyl CoA mutase and new insights into the free radical mechanism". Structure. 6 (6): 711–720. doi:10.1016/S0969-2126(98)00073-2. PMID 9655823.
41. Evans JC, Huddler DP, Hilgers MT, Romanchuk G, Matthews RG, Ludwig ML (March 2004). "Structures of the N-terminal modules imply large domain motions during catalysis by methionine synthase". Proceedings of the National Academy of Sciences of the United States of America. 101 (11): 3729–3736. Bibcode:2004PNAS..101.3729E. doi:10.1073/pnas.0308082100. PMC 374312. PMID 14752199.

• Medicine

• B vitamins
• Organocobalt compounds
• Cofactors
• Vitamin B12
• Corrinoids